Sarvodaya Hospital, Faridabad Becomes India’s First Theranostics Center to Offer Terbium-161 PSMA Therapy for Advanced Prostate Cancer Patients

June 02, 2025 11:30 AM IST | By Businesswire India
 Sarvodaya Hospital, Faridabad Becomes India’s First Theranostics Center to Offer Terbium-161 PSMA Therapy for Advanced Prostate Cancer Patients
Image source: Businesswire India
Business Wire India
Reinforcing its commitment to pioneering advanced cancer care, Sarvodaya Hospital, Faridabad, Delhi NCR is proud to announce that it has become the first Theranostics and Nuclear Medicine center in India to offer Terbium-161 PSMA therapy for prostate cancer treatment. This marks a significant milestone, positioning Sarvodaya Hospital as a leader in providing comprehensive cancer care. Furthermore, this cutting-edge nuclear therapy represents a notable step in cancer treatment, offering new hope to patients with advanced metastatic castration resistant/hormone refractory prostate cancer.

Further strengthening its role at the forefront of cancer innovation, Sarvodaya Cancer Institute has also introduced CAR-T Cell therapy, one of the most advanced treatments for blood cancers like leukemia, lymphoma, and multiple myeloma. With this, the hospital now offers complete cancer care, from diagnosis to advanced treatment, all under one roof.

Dr. Swagat Dash, HOD & Senior Consultant - Nuclear Medicine, Sarvodaya Cancer Institute, Sarvodaya Hospital, Faridabad, leading the initiative stated, "The introduction of this groundbreaking therapy in India will bring renewed hope to patients battling with advanced prostate cancer. This marks a significant step in precision oncology, and the team at Sarvodaya remains committed to delivering advanced and cutting-edge cancer care.”

Dr. Dinesh Pendharkar, Director, Sarvodaya Cancer Institute, Sarvodaya Hospital, Faridabad, said “At Sarvodaya Hospital, we remain committed to treat patients through evidence-based techniques as well as to improve outcomes for the patients. We are honored to pioneer this revolution in India because terbium-161 PSMA therapy represents a novel approach to treat advanced prostate cancer. We are shifting the landscape in terms of what complete cancer care means with CAR-T Cell therapy as well as Theranostics.”


About Sarvodaya Healthcare

Sarvodaya Healthcare is a pioneering healthcare group that has been serving the community for over the last 34 years. With a commitment to affordable and top-class medical facilities and compassionate care, the journey began three decades ago with a mission: Sarve Santu Niramaya, which translates to "Good health for all" regardless of background or ailment. The vision was to provide accessible and high-quality medical services.

Over the years, the trust and support of the patients and their families have propelled Sarvodaya forward. From a modest 5-bedded clinic, the hospital has grown into an 800-bedded healthcare group encompassing tertiary and secondary care hospitals, nursing and paramedic institutes, health clinics, diagnostic and imaging centers, and dialysis facilities across Faridabad, Greater Noida, Delhi, and other cities in the National Capital Region.

Sarvodaya Healthcare harnesses cutting-edge technology alongside a team of skilled specialists to offer advanced treatments across various super specialties. These include Cancer Care and Bone Marrow Transplants, Nuclear Medicine and Theranostics, Radiotherapy, Orthopedics and Robotic Joint Replacement, Neurosciences, Pediatric to Adult Cardiology and Cardiac Surgeries, Dialysis and Kidney Transplants, Minimal Access Surgery, Gastroenterology and GI Surgeries, Urology and LASER Urological Surgeries, ENT and Cochlear Implants, Diabetes and Endocrinology, Plastic and Reconstructive Surgery, Rheumatology, Pulmonology, and more.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.